Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Trial Profile

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Regorafenib (Primary) ; Clobetasol
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ReDOS
  • Most Recent Events

    • 22 Mar 2018 Planned End Date changed from 22 Jun 2020 to 22 Jun 2019.
    • 07 Feb 2018 Planned End Date changed from 1 Dec 2020 to 22 Jun 2020.
    • 20 Jan 2018 Primary endpoint (Proportion of patients in each arm who complete 2 courses of treatment and who intend to initiate course 3 if no progression is noted on the planned disease evaluation) has been met. according to results presented at the 2018 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top